Design, synthesis, and structure–activity relationship of novel and effective apixaban derivatives as FXa inhibitors containing 1,2,4-triazole/pyrrole derivatives as P2 binding element
摘要:
Four series of novel and potent FXa inhibitors possessing the 1,2,4-triazole moiety and pyrrole moiety as P2 binding element and dihydroimidazoleitetrahydropyrimidine groups as P4 binding element were designed, synthesized, and evaluated for their anticoagulant activity in human and rabbit plasma in vitro. Most compounds showed moderate to excellent activity. Compounds 14a, 16, 18c, 26c, 35a, and 35b were further examined for their inhibition activity against human FXa in vitro and rat venous thrombosis in vivo. The most promising compound 14a, with an IC50 (FXa) value of 0.15 mu M and 99% inhibition rate, was identified for further evaluation as an FXa inhibitor. (C) 2016 Elsevier Ltd. All rights reserved.
Design, synthesis, and structure–activity relationship of novel and effective apixaban derivatives as FXa inhibitors containing 1,2,4-triazole/pyrrole derivatives as P2 binding element
摘要:
Four series of novel and potent FXa inhibitors possessing the 1,2,4-triazole moiety and pyrrole moiety as P2 binding element and dihydroimidazoleitetrahydropyrimidine groups as P4 binding element were designed, synthesized, and evaluated for their anticoagulant activity in human and rabbit plasma in vitro. Most compounds showed moderate to excellent activity. Compounds 14a, 16, 18c, 26c, 35a, and 35b were further examined for their inhibition activity against human FXa in vitro and rat venous thrombosis in vivo. The most promising compound 14a, with an IC50 (FXa) value of 0.15 mu M and 99% inhibition rate, was identified for further evaluation as an FXa inhibitor. (C) 2016 Elsevier Ltd. All rights reserved.
Novel intermediate and polymorphs of 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetra hydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide and process thereof
申请人:THIRUMALAI RAJAN Srinivasan
公开号:US20150353541A1
公开(公告)日:2015-12-10
The present invention provides a novel intermediate as well as novel polymorphs of 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide compound represented by the following structural formula-1 and processes for their preparation.
[EN] NOVEL INTERMEDIATE AND POLYMORPHS OF 1-(4-METHOXYPHENYL)-7-OXO-6-[4-(2-OXOPIPERIDIN-1-YL)PHENYL]-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3,4-c] PYRIDINE-3-CARBOXAMIDE AND PROCESS THEREOF<br/>[FR] NOUVEL INTERMÉDIAIRE ET NOUVEAUX POLYMORPHES DU 1-(4-MÉTHOXYPHÉNYL)-7-OXO-6-[4-(2-OXOPIPÉRIDIN-1-YL)PHÉNYL]-4,5,6,7-TÉTRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDINE-3-CARBOXAMIDE ET PROCÉDÉ S'Y RAPPORTANT
申请人:MSN LAB LTD
公开号:WO2014108919A2
公开(公告)日:2014-07-17
THE PRESENT INVENTION PROVIDES NOVEL INTERMEDIATE AND NOVEL POLYMORPHS OF 1-(4-METHOXYPHENYL)-7-OXO-6-[4-(2-OXOPIPERIDIN-1-YL) PHENYL]-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3,4-c]PYRIDINE-3-CARBOXAMIDE AND PROCESSES FOR THEIR PREPARATION